All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the COLYM 2022 Annual Meeting, the Lymphoma Hub spoke with Matthew Wilson, Beatson West of Scotland Cancer Centre, Glasgow, UK. We asked, Is central nervous system (CNS) prophylaxis warranted in DLBCL?
Is CNS prophylaxis warranted in DLBCL?
Wilson discusses the topic of CNS relapse in DLBCL and explains that there is a lack of data in support of a clear prophylactic treatment strategy. Wilson summarizes the latest data for the use of high-dose methotrexate and describes how it is may be used sparingly. Advancements in novel molecular techniques to screen patients at baseline for CNS disease hold great promise for guiding future prophylactic treatment regimens.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Lenalidomide and rituximab combination for R/R PCNSL-DLBCL patients
This open-label, multicenter, singe-arm, prospective, phase II trial the efficacy of rituximab together with lenalidomide was assessed in DLBCL-PCNS patients.
Published case study – First case of DLBCL presenting as bilateral internal auditory canal lesions and mimicking bilateral schwannomas
Last month, in a Letter to the Editor of the Canadian Journal of Neurological Sciences, Nevena Markovic from...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox